Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ernst & Young Bullish On Medtech's Fusion With Innovation

Executive Summary

The medtech industry grew by 5% last year, with revenues from US- and Europe-based medtechs reaching $364.4bn in 2016. Meanwhile, net income rose by 17% to reach $16bn in 2016, according to Ernst & Young's annual medtech "Pulse of the industry" report, released today to coincide with The MedTech Conference in San Jose. With global funding expanding, in particular in Asia, medtechs are well positioned for growth, but only those willing to embrace the digital revolution are poised to win.

You may also be interested in...



New Report Spotlights Intensifying Rivalry Between Tech And Health-Care Companies

More than 75% of Fortune 500 life-science companies may fall out of that ranking by 2023 amid rising competition from tech giants like Apple, Microsoft and Alphabet, as well as smaller tech players that offer data-driven health services and products that meet the needs of a changing value-based and consumer-driven health-care environment, according to a new Ernst & Young report.

VC Deals Analysis: Liquid Biopsy Summons Yet Another Top A-Lister

While August may have broken the short summer bull run, last month's batch of venture fundraisings did have one redeeming feature – it recorded the biggest Series A round this year to date, a $50m deal by liquid biopsy company Karius.

Market Intel: How 3D Printing Can Enhance And Expand Medtech Opportunities

3D printing has been hailed as a potentially game-changing technology for different industries. Biomedical applications, in particular, have garnered much attention when patients were able to receive 3D-printed, customized, lifesaving medical interventions. But aside from these niche markets for personalized medical devices, can 3D printing ever become mainstream in health care? This article, a guest column from leaders at the Boston Consulting Group, explores what the benefits of 3D-printed devices are and how they are driving the uptake of this technology. It also assesses how fast this adoption is happening and evaluates how – and in which biomedical applications and device markets – 3D printing could best enhance products and allow medtech manufacturers to grow their business.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT121532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel